TA
Tarsons Products Ltd (TARSONS)
₹341.95
Mkt cap
₹1,629 Cr
P/E ratio
138.00
P/B
2.87
Div yield
0.00%
ROE
2.44%
ROCE
4.59%
EPS (TTM)
₹2.48
Book value
₹119
52W range
164–375
Sector
Healthcare
Price history
Previous close
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals [1]
NSE TARSONSBSE 543399
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBullish
52-week range
−8.81% from high₹342
₹164+107.94% from low₹375
Current
₹341.95
Prev close
₹335.00
Day
+2.07%
Price performance
1D
+2.07%
1W
+1.17%
1M
+1.62%
3M
+15.37%
6M
+88.27%
1Y
+11.29%
YTD
+45.36%
Financials
Revenue, profit & margin
P/E ratio
138.0×
TARSONS is 317% above the sector median of 33.1×
TARSONS138.0×
Sector median33.1×
| Dec 2021 | Mar 2022 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.66 | 84.94 | 61.79 | 105.72 | 84.80 | 99.25 | 95.68 | 112.69 | 91.36 | 102.33 | 107.89 | 120.93 | 110.24 | |
| Expenses | 37.52 | 40.61 | 38.91 | 75.48 | 66.04 | 73.94 | 66.04 | 75.67 | 66.66 | 74.88 | 76.37 | 86.66 | 84.25 | |
| Operating Profit | 33.14 | 44.33 | 22.88 | 30.24 | 18.76 | 25.31 | 29.64 | 37.02 | 24.70 | 27.45 | 31.52 | 34.27 | 25.99 | |
| OPM % | 46.90% | 52.19% | 37.03% | 28.60% | 22.12% | 25.50% | 30.98% | 32.85% | 27.04% | 26.82% | 29.21% | 28.34% | 23.58% | |
| Other Income | 2.46 | 2.58 | 3.24 | 3.38 | 2.91 | 8.43 | 0.85 | 3.78 | 3.34 | 5.80 | 7.07 | 6.83 | 5.98 | |
| Interest | 1.37 | 0.45 | 2.51 | 4.25 | 4.32 | 4.84 | 5.03 | 5.20 | 5.07 | 5.18 | 6.05 | 6.25 | 6.27 | |
| Depreciation | 5.35 | 7.24 | 10.06 | 12.33 | 11.03 | 14.03 | 17.41 | 20.03 | 19.94 | 22.48 | 25.04 | 29.08 | 27.02 | |
| Profit before tax | 28.88 | 39.22 | 13.55 | 17.04 | 6.32 | 14.87 | 8.05 | 15.57 | 3.03 | 5.59 | 7.50 | 5.77 | -1.32 | |
| Tax % | 25.66% | 24.89% | 26.72% | 39.50% | 36.39% | 30.80% | 34.66% | 34.49% | 41.25% | 40.61% | 32.93% | 27.56% | 9.09% | |
| Net Profit | 21.47 | 29.46 | 9.93 | 10.32 | 4.02 | 10.29 | 5.26 | 10.20 | 1.78 | 3.32 | 5.04 | 4.18 | -1.44 | |
| EPS in Rs | 4.04 | 5.54 | 1.87 | 1.94 | 0.76 | 1.93 | 0.99 | 1.92 | 0.33 | 0.62 | 0.95 | 0.79 | -0.27 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −5.20% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 10 Aug '26◦ |
| Earnings day | −5.20% |
| +1 day | −0.22% |
| +5 days | +7.38% |
| +15 days | +9.76% |
| +30 days | +7.00% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202647.30%Promoter
Promoters47.30%
FIIs0.15%0.72
DIIs0.10%0.09
Public52.44%0.79
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Poly Medicure | ₹1,726.00 | 54.67 | 17,495 | 0.20% | 85 | −7.57% | 525 | +30.30% | 12.50% |
| Molbio Diagnosti | ₹1,288.30 | 59.47 | 14,846 | 0.00% | 53 | +347.79% | 408 | +309.57% | 18.48% |
| Fischer Medical | ₹33.15 | 94.61 | 2,316 | 0.15% | 4 | −22.02% | 82 | +249.49% | 11.38% |
| Tarsons Products | ₹306.10 | 137.55 | 1,629 | 0.00% | −1 | −180.90% | 110 | +20.67% | 4.59% |
| Q-Line Biotech | ₹696.95 | 28.79 | 1,626 | 0.00% | 34 | +147.29% | 198 | −8.59% | 22.46% |
| Laxmi Dental | ₹197.95 | 31.32 | 1,089 | 0.00% | 10 | +22.77% | 75 | +13.87% | 15.05% |
| Vasa Denticity | ₹420.40 | 60.26 | 729 | 0.00% | 4 | +45.99% | 82 | +36.90% | 9.21% |
| Median: 17 Co. | ₹342.40 | 33.09 | 603 | 0.00% | 4 | +19.77% | 75 | +21.48% | 15.14% |
Filings
Annual reports5
Concall transcripts51
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Sep - Newspaper Publication for 43rd Annual General Meeting -Completion of dissemination of Notice and Annual Report for FY 2025-26.Intimation Under Regulation 36(1)(B) Of SEBI (LODR) Regulations, 2015 - Letter To Shareholders 2 Sep - Tarsons sent shareholders web links for FY26 annual report and 43rd AGM notice.Business Responsibility and Sustainability Reporting (BRSR) 2 Sep - Tarsons submitted its FY2025-26 Business Responsibility and Sustainability Report to BSE and NSE.Notice Of The 43Rd Annual General Meeting Of The Company For The Financial Year Ended March 31, 2026 2 Sep - 43rd AGM on 24 Sep 2026; approve RPT up to ₹3,750 million and ₹41.39 million remuneration waiver.Notice Of The 43Rd Annual General Meeting Of The Company For The Financial Year Ended March 31, 2026 2 Sep